Biomarin Pharmaceutical (BMRN) Short term Debt (2012 - 2026)

Biomarin Pharmaceutical (BMRN) has 12 years of Short term Debt data on file, last reported at $494.8 million in Q2 2024.

• Quarterly Short term Debt changed N/A year-over-year to $494.8 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $494.8 million (changed N/A YoY) and the FY2023 annual result came in at $493.9 million, up 3001.27% from the prior year.
• Short term Debt held at $494.8 million in Q2 2024, from $494.4 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $494.8 million in Q2 2024 to a low of $15.9 million in Q4 2022.
• A 5-year average of $206.5 million and a median of $56.1 million in 2021 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2020 — Short term Debt jumped 3642.9% — and 2021, when it sank 91.58%.
• Tracing BMRN's Short term Debt over 5 years: stood at $374.3 million in 2020, then sank by 87.11% to $48.2 million in 2021, then slumped by 66.98% to $15.9 million in 2022, then surged by 3001.27% to $493.9 million in 2023, then increased by 0.19% to $494.8 million in 2024.
• The last three Short term Debt figures came in at $494.8 million (Q2 2024), $494.4 million (Q1 2024), and $493.9 million (Q4 2023), per Business Quant data.